Loading company…
Noscendo offers DISQVER, a sequencing-based diagnostic platform that detects over 16,000 microbes from one patient sample.
Founded in 2018 in Duisburg, Germany, Noscendo GmbH sells diagnostics mainly to hospitals and health insurance providers in Europe, particularly Germany. Its DISQVER platform uses next-generation sequencing of cell-free DNA from blood to diagnose bloodstream infections and sepsis, with results in about 24 hours. Its Series A round in April 2020 drew new investors Earlybird Venture Capital, JIH Family Office and Paua Ventures, plus returning investors High-Tech Gründerfonds and Wieland Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in